logo
Regular cannabis use can cause a serious vomiting syndrome. Should people be warned?

Regular cannabis use can cause a serious vomiting syndrome. Should people be warned?

CBC10 hours ago
When Brittany Ramsey started experiencing "awful stomach episodes" she thought it must've been side effects of the medication she was taking to manage her diabetes.
But after a particularly gruelling episode where she just could not stop vomiting — not being keep down even small sips of water — that landed her in hospital, Ramsey knew something felt different about what she was experiencing.
"From then, the episodes got worse and worse, and closer together," said Ramsey, a 35-year-old operations trainer at a financial firm in Cincinnati, Ohio. "From 2021 to 2024 … three years, I was hospitalized 29 times. Five ambulance trips – one actually had to pick me up on the side of the road because I couldn't make it to the hospital."
After years of undergoing, at times, invasive testing procedures to rule out Crohn's disease, gastroparesis and diverticulitis, a doctor told Ramsey about cannabis hyperemesis syndrome (CHS).
In recent years some emergency rooms have been seeing an uptick in visits due to cyclic episodes of uncontrollable vomiting in cannabis users, often characterized by experiencing temporary relief with hot showers and baths. Since it was first identified in medical literature in 2004, CHS cases have increased, possibly because of greater cannabis access or higher THC potency of products.
Public health researchers suggest more awareness of CHS within the health-care system is needed for cannabis users to get the information and support they need.
More CHS cases in the ER
CHS is characterized by "severe and persistent vomiting" and is usually seen in people who have been using cannabis several times a week for multiple years, said Jamie Seabrook, a professor at the Department of Epidemiology and Biostatistics at Western University in London, Ont.
Ramsey said she'd been smoking at least once a day for over 10 years since she was 18 when she first started experiencing CHS symptoms in 2017.
A 2022 study by researchers at the Ottawa Hospital Research Institute looked at the rate of emergency department visits for CHS after recreational cannabis was legalized and commercialized in Ontario, looking at nearly 13,000 CHS-related hospitalizations in Ontario from 8,140 individuals between 2014 and 2021.
The study, published in the Journal of the American Medical association (JAMA), found that emergency department visits related to CHS had increased by 13-fold over a period of nearly eight years. The study doesn't show what caused the change, but the authors noted that the biggest increase in visits came not after legalization in 2018 but after Ontario allowed expansion of retail stores in 2020, which coincided with the COVID-19 pandemic.
Though we don't have numbers how many people have been diagnosed or hospitalized with CHS, online communities are filled with people looking for support.
Ramsey is part of one of them — a CHS Facebook group described as a "safe place to recover and learn" with 3,000 members. The largest CHS Facebook group has 31,000 members. On Reddit, the group r/CHSinfo has 20,000 members, with discussions ranging from tips on how to manage episodes and personal anecdotes about repeated hospitalizations.
Seabrook, who co-authored a recent review of existing research on CHS in youth, said there's been an "explosion" of people showing up in some North American emergency rooms with CHS within the last seven to eight years.
The Ottawa Hospital Research Institute study showed that other cannabis-related emergency room visits, including for intoxication and dependence, saw a substantial increase starting in early 2020 as well.
Surge in THC potency since the 1980s
Seabrook said a likely reason for increased rates of CHS is the high THC potency of cannabis products today.
THC is the compound in cannabis that is responsible for the sensation of a high most people experience when consuming it. When its potency increases, so do its harmful effects.
Different strains of the plant will have different concentrations of active compounds, measured by percentage of total weight or volume. On average, THC content is much higher today than it used to be.
"The potency of THC was only about three per cent in the 1980s and today, according to Health Canada, the average is 15 per cent with some strains as high as 30 per cent," Seabrook said, citing Health Canada numbers for "fresh or dried herb material."
"So we're talking a 400 per cent or higher increase in the potency."
For "chemically concentrated extracts," such as hash oil, shatter, budder and wax, the typical potency can be up to 90 per cent, according to Health Canada data.
"The potency, I think, is what's causing the illnesses to become more and more prevalent, because they're smoking a lot more potent stuff," Ramsey said. "And that's the same with me. When I first started smoking, it was my brother's homegrown stuff, versus getting it from friends and dispensaries out in California, where it does get stronger and stronger."
"I feel like maybe before just making marijuana available to the masses, maybe some of these things should have been looked into. You know, too much of anything might be bad," said Ramsey.
Lawsuit against Aurora Cannabis cites CHS
A lawsuit was recently brought against Canadian cannabis production company Aurora Cannabis for alleged negligence of failing to warn consumers about the potential risk for developing CHS from the regular use of its products. The lawsuit was certified by the Ontario Superior Court of Justice last month, meaning it can proceed as a class action.
Margaret Waddell, the lawyer prosecuting the case, said she hopes that if the lawsuit is successful, it could have an industry-wide effect on including CHS in their product labelling.
"Ideally, Health Canada will require them at some point," Waddell said. Health Canada does require cannabis manufacturers to warn customers about specified risks — including psychotic symptoms, addiction and dependence — but Waddell said there aren't currently any requirements to specifically include CHS in those warnings.
Aurora Cannabis declined to comment on the lawsuit, writing in an emailed statement: "It is the company's practice not to comment on legal matters beyond information that is made available to the public."
"Information that [CHS] exists is very important," Seabrook said. "In schools, in health-care settings – whether that's neurologists, psychiatrists, [emergency room] doctors – and public health campaigns, so people can make a better informed decision about their cannabis use."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations
MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Globe and Mail

time3 hours ago

  • Globe and Mail

MRNA Stock Jumps on CDC's Revised RSV Vaccine Recommendations

Shares of Moderna MRNA rose nearly 6% yesterday after the U.S. Centers for Disease Control and Prevention ('CDC') adopted new recommendations for the use of RSV vaccines in the upcoming respiratory virus season. The revised recommendations lower the recommended age for RSV vaccination. Now, adults aged 50-59 who are at higher risk of severe illness from the disease are advised to receive a single dose of the vaccine. The previous CDC guidance recommended RSV vaccines for people aged 75 and older, as well as those aged between 60-74 who were at high risk of the disease. Per the CDC's website, this recommendation was officially adopted last week by the current HHS secretary, Robert F. Kennedy, Jr. Although the CDC director typically accepts or rejects such recommendations, the position is currently vacant, so Kennedy fulfilled that role. President Trump has backed Susan Monarez as his nominee for the post, but her appointment is still pending confirmation by the U.S. Senate. The broader recommendations come as a surprise because the members of the CDC's advisory committee — who initially made the recommendation earlier this year — were all removed by RFK Jr. last month. MRNA Stock Price Performance Year to date, the stock has lost 27% compared with the industry 's 2% decline. How Does the Revised CDC Guidance Benefit Moderna? The expanded CDC recommendations widen Moderna's addressable market for its RSV vaccine, mResvia. By lowering the recommended age group, the guidance opens up a new segment of eligible patients who were previously excluded. Moderna is one of a handful of companies marketing an RSV vaccine. Though mResvia was initially approved last year for use in people aged 60 and older, the FDA expanded its label last month to include high-risk individuals aged between 18-59. Despite commercially launching the vaccine last year, mResvia sales were modest as it was approved and recommended later in the contracting season. By that point, many people had already completed their vaccinations with either GSK 's GSK Arexvy or Pfizer 's PFE Abrysvo. RSV vaccines gained traction in 2023 with the initial approvals of Arexvy and Abrysvo — the first FDA-approved RSV vaccines. At the time, the CDC issued blanket approvals for use among individuals aged 60 and older. However, the CDC later narrowed that guidance, which trimmed the target market last year. That, combined with the earlier availability of GSK and Pfizer's offerings, gave both companies a dominant position over Moderna. Both GSK and Pfizer vaccines are already approved for use in individuals aged 60 and older. While GSK's Arexvy is approved for use in high-risk individuals aged 50-59, PFE's Abrysvo is approved for use in high-risk people aged 18-59. The Pfizer vaccine is also approved for use in infants through maternal immunization. MRNA's Zacks Rank Moderna currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Moderna, Inc. (MRNA): Free Stock Analysis Report This article originally published on Zacks Investment Research (

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

Globe and Mail

time3 hours ago

  • Globe and Mail

Will The Decline in Legacy Drugs Pull Down BMY's Top Line?

BMY legacy portfolio comprises Eliquis, Revlimid, Pomalyst, Sprycel and Abraxane. Revenues for the Legacy Portfolio plunged 20% in the first quarter to $5.64 billion due to the continued generic impact on Revlimid, Pomalyst, Sprycel and Abraxane, as well as the effects of the U.S. Medicare Part D redesign. Blood thinner drug Eliquis' sales of $3.56 billion were down 4% due to the impact of Medicare Part D redesign in the United States. The company expects sales to steadily increase in the second half of 2025 due to the elimination of the coverage gap. Multiple myeloma (MM) drug Revlimid revenues plummeted 44% to $936 million due to lower demand on account of generic erosion. MM drug Pomalyst generated sales of $658 million, down 24% year over year. Leukemia drug Sprycel sales nosedived 53% year over year to $175 million due to generic competition. Abraxane revenues declined 52% to $105 million. While drugs like Reblozyl, Breyanzi, Camzyos and Opdualag have enabled BMY to stabilize its revenue base, an important point to consider is that the legacy portfolio sales accounted for 50% of total sales in the first quarter. Competition for BMY's Key Drugs BMY's growth portfolio primarily comprises Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, Abecma, Zeposia, Breyanzi, Camzyos, Sotyku, Krazati and others. Oncology is a key therapeutic area of focus for Bristol Myers, which is developing and delivering transformational medicines in this space. However, BMY faces competition from large pharma companies like Merck MRK and Pfizer PFE. The immuno-oncology space is dominated by Merck's blockbuster drug Keytruda (pembrolizumab). Keytruda is approved for several types of cancer and alone accounts for around 50% of its MRK's pharmaceutical sales. Merck is currently working on different strategies to drive long-term growth of Keytruda. Pfizer has an innovative oncology product portfolio of antibody-drug conjugates (ADCs), small molecules, bispecifics and other immunotherapies that treat a wide range of cancers, including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer. Pfizer also has oncology biosimilars in its portfolio and markets six of them for cancer. BMY's Price Performance, Valuation and Estimates Shares of Bristol Myers have lost 14% year to date compared with the industry 's decline of 0.6%. From a valuation standpoint, BMY is trading at a discount to the large-cap pharma industry. Going by the price/earnings ratio, BMY's shares currently trade at 7.45x forward earnings, lower than its mean of 8.86x and the large-cap pharma industry's 15.09X. The Zacks Consensus Estimate for 2025 earnings per share has moved down to $6.76 from $6.89 in the past 60 days and that for 2026 is down five cents. BMY currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report This article originally published on Zacks Investment Research (

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store